

**REMARKS**

With regard to the above-identified Final Rejection, and subsequent Advisory Action, the Applicants respond to the bases for non-entry of the Response After Final of August 7, 2002. Specifically, on further conversation with the Examiner, the Applicants amend the broad generic claim of the application to specify the conditions claimed to be treatable in dependent Claim 14. With this Response, Claim 14 is cancelled. Thus, the scope of the claim covers conditions treatable with the disclosed compounds. There is no suggestion or teaching the prior art of record for treatment of these conditions with these compounds. It is submitted that this amendment both places the application into condition for allowance, and certainly does not raise any new issue as the subject matter was claimed on filing of the application and should already have been properly considered.

\* \* \* \* \*

Accordingly, entry of the present amendment, reconsideration of all grounds of objection and rejection, withdrawal thereof, and passage of this application to issue are all hereby respectfully solicited.

It should be apparent that the undersigned attorney has made an earnest effort to place this application into condition for immediate allowance. If he can be of assistance to the Examiner in the elimination of any possibly-outstanding

insignificant impediment to an immediate allowance, the Examiner is respectfully invited to call him at his below-listed number for such purpose.

Allowance is solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:

  
G. PATRICK SAGE

Dated: September 10, 2002  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007-3856  
(616) 382-0030


Enclosure: Postal Card Receipt,  
Claim amendments,  
One (1) month extension fee of \$110

\* \* \* \* \*

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR DEFECT IN THE ATTACHED CHECK, 37 CFR § 1.17 FEES, OR ANY EXTENSION OF TIME FEES UNDER 37 CFR § 1.136(a)(3), OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08-3220.

- 1 - (clean)

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a 5HT<sub>3</sub> or neuronal nicotinic receptor antagonist, selected from emesis, cerebellar tremor, and appetite disorders, comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R\* is  $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$


wherein  $n+m = 0, 1, \text{ or } 2$

wherein R<sup>1</sup> through R<sup>7</sup> are independently selected from the group consisting of hydrogen and lower-alkyl C<sub>1</sub>-C<sub>6</sub>, wherein R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrogen and lower-alkyl C<sub>1</sub>-C<sub>6</sub> or together represent lower-alkylene  $-(CH_2)_x-$  wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose.

- 1 - (amended)

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a 5HT<sub>3</sub> or neuronal nicotinic receptor antagonist, selected from emesis, cerebellar-tremor, and appetite disorders, comprising the step of administering to the said living animal an

amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R\* is  $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein  $n+m = 0, 1, \text{ or } 2$

wherein R<sup>1</sup> through R<sup>7</sup> are independently selected from the group consisting of hydrogen and lower-alkyl C<sub>1</sub>-C<sub>6</sub>, wherein R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrogen and lower-alkyl C<sub>1</sub>-C<sub>6</sub> or together represent lower-alkylene  $-(CH_2)_x-$  wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose.

The Firm of  
**HUESCHEN AND SAGE PLLC**  
**ATTORNEYS AND COUNSELORS**  
500 COLUMBIA PLAZA  
350 EAST MICHIGAN AVENUE  
KALAMAZOO, MICHIGAN 49007-3856

**State Bank of Caledonia**  
71-50172A

71059

09/10/2002

TO THE  
DER OF

Commissioner of Patents &amp; Trademarks

\$ \*\*110.00

DOLLARS

One Hundred Ten and 00/100\*\*\*\*\*

Commissioner of Patents  
Washington, DC 20231

G. PATRICK SAGE, ATTY. AT LAW



MO:

MERZ 30 - SN 09/597,102

07 1059 10724058791: 02 2854 011

SECURITY FEATURES: MICRO PRINT TOP &amp; BOTTOM BORDERS - COLORED PATTERN - ARTIFICIAL WATERMARK ON REVERSE SIDE - MISSING FEATURE INDICATES A COPY

Applicant : Christopher Graham Raphael PARSONS, et al.  
Serial No. : 09/597,102  
Filed : June 20, 2000  
1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3  
NICOTINIC RECEPTOR

Applicant : Christopher Graham Raphael PARSONS, et al.  
Serial No. : 09/597,102  
Filed : June 20, 2000  
Title : 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3  
AND NEURONAL NICOTINIC RECEPTOR  
ANTAGONISTS  
Art Unit : 1617  
Examiner : Shaojia JAING, PhD

and

Response and Amendment After Final, Claims amendments, and  
\$110 extension fee.  
MERZ 30/dln  
September 10, 2002

